Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Galapagos NV

Biotech R&D: Alpine vs. Galapagos - A Decade of Innovation

__timestampAlpine Immune Sciences, Inc.Galapagos NV
Wednesday, January 1, 201412199547111110000
Thursday, January 1, 201516054000129714000
Friday, January 1, 201623316000139574000
Sunday, January 1, 201710626000218502000
Monday, January 1, 201828970000322876000
Tuesday, January 1, 201935847000427320000
Wednesday, January 1, 202027185000523667000
Friday, January 1, 202158742000491707000
Saturday, January 1, 202270243000515083000
Sunday, January 1, 202380904000241294000
Loading chart...

Data in motion

Innovation in Biotech: A Comparative Analysis

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alpine Immune Sciences, Inc. and Galapagos NV have demonstrated contrasting approaches to R&D investment.

A Decade of Investment

From 2014 to 2023, Galapagos NV consistently outspent Alpine Immune Sciences, with R&D expenses peaking in 2020 at over 500% more than Alpine's. However, Alpine has shown a remarkable growth trajectory, increasing its R&D spending by approximately 560% from 2014 to 2023.

The Innovation Race

While Galapagos NV's R&D spending saw fluctuations, Alpine's steady increase suggests a strategic focus on innovation. In 2023, Alpine's R&D expenses reached 80% of Galapagos's, highlighting its growing emphasis on research. This trend underscores the dynamic nature of the biotech industry, where strategic investments can shift competitive landscapes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025